⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858080 | 0.85 | MMP1 (0.52) | — | |
| SCHEMBL1310321 | 0.84 | EPHX1 (0.54) | — | |
| SCHEMBL2552861 | 0.82 | MMP1 (0.41) | — | |
| SCHEMBL2802349 | 0.82 | EPHX1 (0.60) | — | |
| SCHEMBL2552858 | 0.82 | MMP1 (0.41) | — | |
| SCHEMBL18754166 | 0.80 | MMP1 (0.40) | — | |
| SCHEMBL9152050 | 0.79 | MMP1 (0.43) | — | |
| SCHEMBL149370 | 0.79 | — | — | |
| SCHEMBL18330645 | 0.79 | MMP1 (0.39) | — | |
| SCHEMBL6583643 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216749-A1 | Combination Therapy for Neuroprotection | S.H. PHARMA., LTD (KR) | 2010-08-26 | — | — | US | claimed |
| WO-2009045083-A2 | COMBINATION THERAPY FOR NEUROPROTECTION | S.H. PHARMA., LTD (KR) | 2009-04-09 | — | — | WO | claimed |
| WO-2017112824-A2 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS | AMGEN INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2015031725-A1 | TRANSITION METAL-CATALYZED IMIDATION OF ARENES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-03-05 | — | — | WO | disclosed |
| US-20130216538-A1 | Compositions and Methods for Treating Inflammatory Disorders | DOMANTIS LIMITED (GB) | 2013-08-22 | — | — | US | disclosed |
| US-8314141-B2 | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314141-B2 | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-20 | — | — | US | disclosed |
| US-8304218-B2 | Enzymatic peracid production using a cosolvent | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120094342-A1 | ENZYMATIC PERACID PRODUCTION USING A COSOLVENT | DUPONT US HOLDING, LLC | 2012-04-19 | — | — | US | disclosed |
| EP-2409985-A2 | Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2319532-A1 | Recombinant dengue virus containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 3, or 4 | The Government of the United States of America, represented by The Secretary, Department of Health and Human Services (US) | 2011-05-11 | — | — | EP | disclosed |
| US-20100216749-A1 | Combination Therapy for Neuroprotection | S.H. PHARMA., LTD (KR) | 2010-08-26 | — | — | US | disclosed |
| US-20100040631-A1 | Combination Therapy of HIV Using Fusion/Entry Inhibitors Targeting GP41 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| US-20090281142-A1 | THIAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7598252-B2 | Compounds specific to adenosine A, receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090143312-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143312-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2009045083-A2 | COMBINATION THERAPY FOR NEUROPROTECTION | S.H. PHARMA., LTD (KR) | 2009-04-09 | — | — | WO | disclosed |
| US-20070020625-A1 | Sequence of the photorhabdus luminescens strain tt01 genome and uses | DUCHAUD ERIC | 2007-01-25 | — | — | US | disclosed |